Incyte’s Jakafi Gets Broad Label, Early Approval For Myelofibrosis

Incyte Corp. hits the trifecta – a first-in-class, first-in-disease and first launch with the Nov. 16 FDA approval of Jakafi (ruxolitinib) for treatment of the progressive bone marrow cancer.